![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Population Pharmacokinetic Analysis of
Velpatasvir, a Pangenotypic HCV NS5A Inhibitor,
in Healthy and Hepatitis C Virus-Infected Subjects
|
|
|
Reported by Jules Levin
17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, 8-10 June 2016, Washington, DC, USA
Brian Kirby,1 Erik Mogalian,1 Yuying Gao,2 Kavitha Bhasi,1 Anita Mathias1
1Gilead Sciences, Inc., Foster City, California, USA; 2Quantitative Solutions, Inc., Menlo Park, California
![Clin1](../images/062916/062916-3/Clin1.gif)
![Clin2](../images/062916/062916-3/Clin2.gif)
![Clin3](../images/062916/062916-3/Clin3.gif)
![Clin4](../images/062916/062916-3/Clin4.gif)
![Clin5](../images/062916/062916-3/Clin5.gif)
![Clin6](../images/062916/062916-3/Clin6.gif)
![Clin7](../images/062916/062916-3/Clin7.gif)
![Clin8](../images/062916/062916-3/Clin8.gif)
![Clin9](../images/062916/062916-3/Clin9.gif)
![Clin10](../images/062916/062916-3/Clin10.gif)
![Clin11](../images/062916/062916-3/Clin11.gif)
![Clin12](../images/062916/062916-3/Clin12.gif)
![Clin13](../images/062916/062916-3/Clin13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|